LIVEN Pharma Limited.
Live With Health

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED SEPTEMBER 30, 2025.

LIVEN Pharma Limited.
Live With Health

49 KM LAHORE MULTAN ROAD PAKISTAN
www.liven-pharma.com info@liven-pharma.com
+92-3-111-0-LIVEN

Table of contents

COMPANY'S INFORMATION 3
VISION AND MISSION STATEMENT 4
PROFILE OF DIRECTORS 5
DIRECTOR REPORT 7
ڈائریکٹرز کی رپورٹ 12
CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED SEPTEMBER 30, 2025 16

COMPANY'S INFORMATION

Board of Directors

Mr. Atif Hussain
Chairman

Mr. Kaashif Hussain
Chief Executive Officer

Ms. Firdous Shakir
Executive Director

Mr. Umar Mujib Shami
Non-Executive Director

Mr. Usman Mujib Shami
Non-Executive Director

Mr. Ahmad Shoaib Hashmi
Independent Director

Mr. Syed Raza Abbas
Independent Director

Audit Committee

Mr. Ahmad Shoaib Hashmi

Mr. Atif Hussain Siddiqi

Ms. Usman Mujib Shami

Human Resource & Remuneration Committee

Mr. Ahmad Shoaib Hashmi

Mr. Atif Hussain Siddiqi

Ms. Firdous Shakir

Chief Financial Officer

Mr. Muhammad Shah

Company Secretary

Mr. Muhammad Saeed

External Auditors

Reanda Haroon Zakaria Aamir Salman
Rizwan & Co Chartered Accountants

Legal Advisor

Saeed Associates

Share Registrar

F.D Registrar Services (pvt) Ltd

Bankers

Bank Al Habib Limited

Meezan Bank Limited

Registered Office

49-Km Lahore Multan Road Pakistan

+92-3-111-0-45836

info@liven-pharma.com

www.liven-pharma.com

VISION AND MISSION STATEMENT

Our Vision

Our business focus made explicit in this plan, renews our vision and strategic thinking on adding value to our target market segments. From average buyer to high-end institutions we will position ourselves in a manner to differentiate us from box pushers to serious minded totally committed purveyors of safe and reliable products.

Our marketing challenge is to position our product as the high–quality, high value-added yet affordable alternative to existing brands and similar products.

Our challenge is to strengthen our brand by giving the most effective and accurate product, rather than incentive based sales and marketing strategy.

From the import of the basic raw material to the procurement of excipients and packaging material our focus is to target the most reputed and prestigious manufacturers with concerned certifications as our vendors, so that what we produce for our customers is the compilation of the best what is available in the market.

We have long term targets and have set high goals for our short term results, that is why we believe in quality rather than quantity, perfection is our passion and so is the least required quality of our sector i.e. pharmaceutical manufacturing, but we take it seriously rather religiously we believe we have not chosen a business but a duty that is to endeavor ourselves in the service of humanity

Our Mission

Liven is a promise, a hope a life, a driving force more than just a pharmaceuticals manufacturing company endeavored in the business of cure, remedy and quality of life, our mission is to create a better world through our Business activities as well as our CSR activities. LIVEN is a name of a lively healthy and happy life. Welcome to the world of Liven Pharmaceuticals Ltd; where everybody is healthy wealthy and wise. LIVEN name means cause to be more lively, we creates to become more lively, rooted from a name itself we strive in providing healthcare, medicines, pharmaceuticals products and solutions to deprived, distressed and ailed to come to life and lively hood, leading by innovation to meet patient needs, and being a trusted partner for the healthcare community worldwide.

PROFILE OF DIRECTORS

MR. ATIF SIDDIQI - CHAIRMAN OF BOARD OF DIRECTORS

Mr. Atif, an accomplished industrialist, embarked on his professional career in 1999 with the establishment of his first venture, a manufacturing company specializing in empty glass ampoules for the pharmaceutical packaging industry. A graduate in BBA (Bachelors of Business Administration) from Premier College Lahore, he combines strong business acumen with extensive entrepreneurial experience.

Over the course of his career, he has successfully led multiple ventures, including Merchant's Glass, MG Construction, and Textile Temple, each of which has benefited from his strategic vision and hands-on leadership. His deep understanding of manufacturing operations, coupled with his commitment to operational excellence, has been a cornerstone of his professional success. Known for his industrious and perfectionist approach, Mr. Atif has consistently demonstrated the ability to deliver sustainable growth, innovation, and value creation throughout his career.

MR. KAASHIF HUSSAIN SIDDIQIE – CHIEF EXECUTIVE OFFICER & EXECUTIVE DIRECTOR

Mr. Kaashif Hussain is a visionary leader and entrepreneur with a strong academic background in

Business Administration and Software Engineering, specializing in System Analysis and Design. He holds postgraduate degrees including an MBA and an MSc in Information Technology from Al-Khair University, Lahore.

He began his entrepreneurial journey in 1998 by establishing Heavenly Impex, an import business supplying glass packaging materials to pharmaceutical manufacturers in Pakistan. In 1999, he expanded the venture by founding Merchant's Glass, a manufacturing company. Over the years, Mr. Kaashif has also been associated with other successful ventures, including MG Constructions and Textile Temple.

Known for his analytical approach, decisiveness, and optimism, Mr. Kaashif has consistently demonstrated the qualities of a true leader, driving organizations toward growth and success.

MR. UMER MUJIB SHAMI – NON-EXECUTIVE DIRECTOR

Mr. Umer Shami is an accomplished business leader with extensive experience in the oil, real estate, and media sectors. He holds an MBA from the Lahore University of Management Sciences (LUMS) and currently serves as a Director at New Life Developers Ltd., where he oversees real estate projects in Lahore and Gwadar. Under his leadership, Euro Oil has emerged as a growing brand in Pakistan's oil and gas industry. Prior to this role, he served as Chief Executive of Fuel Tech Ltd. A leading fuel distribution company catering to major national and multinational clients. Mr. Umer is widely recognized for his strategic vision and his ability to transform innovative ideas into successful business ventures.

MR. USMAN MUJIB SHAMI – NON-EXECUTIVE DIRECTOR

Mr. Umer Mujib Shami holds a Bachelor's degree from the Institute of Business Administration (IBA), Karachi, one of Pakistan's leading business schools. He further pursued a Master's degree in International Business from Hult International Business School, Shanghai.

In addition to serving as a Board Member of Euro Oil, Mr. Usman manages Pakistan's largest digital media house and acts as a marketing consultant for a premier housing development project in the emerging port city of Gwadar.

Mr. Usman is recognized for his analytical acumen, lean management practices, and dynamic leadership in business development, which distinguish him among top industry executives.

MR. AHMAD SHOAIB HASHMI – INDEPENDENT DIRECTOR

Mr. Ahmad Shoaib Hashmi is a distinguished businessman with extensive experience in the pharmaceutical industry. As a founding member of Mass Pharma, he has served for over 28 years in key leadership roles, including Director of Procurement and Director of International Business. With more than 35 years of professional expertise, his career encompasses pharmaceutical manufacturing, distribution, imports, and international trade.

Mr. Ahmed Shoaib is widely recognized for his strategic leadership and in-depth industry knowledge, having played a pivotal role in driving growth, developing global partnerships, and contributing to the advancement of the pharmaceutical sector. He is also among the pioneers who introduced innovative healthcare technologies in Pakistan, such as Enhanced External Counter pulsation (EECP) treatment for cardiac patients who are unable to undergo invasive procedures.

Ms. FIRDOUS SHAKIR – EXECUTIVE DIRECTOR

Ms. Shakir is a highly experienced professional with over 48 years of expertise in managing human resources and successfully operating small and medium enterprises. She has independently managed a dairy and protein farm, demonstrating strong leadership, organizational management, and operational skills.

Throughout her career, she has developed extensive knowledge in workforce management, supply chain oversight, and sustainable business practices, enabling her to build and maintain efficient business operations. Her ability to adapt to evolving market dynamics and her proven track record in entrepreneurship reflect her strategic mindset and commitment to long-term growth.

MR. SYED RAZA ABBAS JAFFERY – INDEPENDENT DIRECTOR

Mr. Syed Raza Abbas serves on the Board of the Company as a representative of National Investment Trust Limited (NITL), Pakistan's largest and oldest asset management company. He has been associated with NITL since 2001 and currently holds the position of Head of Equities, where he leads the equity investment team and oversees portfolio management across multiple funds. His responsibilities include developing investment strategies, conducting in-depth market research, and ensuring optimal asset allocation to maximize returns for investors.

Prior to joining NITL, Mr. Raza served as Manager Treasury at Doha Bank Limited (Pakistan), where he gained valuable experience in treasury operations, liquidity management, and financial risk mitigation.

Mr. Raza holds an MBA in Banking & Finance and also represents NITL on the boards of several other listed companies. Through his governance roles, he actively contributes to promoting transparency, accountability, and sustainable growth within these organizations.

DIRECTOR REPORT

We are pleased to present the condensed interim financial statements for the period ended September 30, 2025.

Composition of Board

1.	**Male**	**6**
2.	Female	1
Sr. No.	**Category**	**Name**
1	Independent Director	1. Mr. Ahmad Shoaib Hashmi 2. Mr. Syed Raza Abbass
2	Non-Executive Director	1. Mr. Atif Hussain 2. Mr. Umar Mujib Shami 3. Mr. Usman Mujib Shami
3	Executive Director	1. Mr. Kaashif Hussain 2. Ms. Firdous Shakir (Female director)

PRINCIPAL ACTVITIES

The principal activity of the company is manufacturing and sale of pharmaceutical products.

OVERVIEW OF ECONOMY AND BUSINESS

Macroeconomic Overview

During the quarter ended September 30, 2025, Pakistan's macroeconomic environment remained broadly stable. While inflationary pressures and cost dynamics continued to influence business operations, no material economic developments occurred during the period that significantly impacted the Company's performance.

Sector Performance

The pharmaceutical sector continued to demonstrate resilience, supported by sustained demand for essential healthcare products. Ongoing healthcare needs and regulatory engagement remained key drivers supporting sector continuity during the quarter.

Industry Challenges

The sector continued to face challenges relating to regulatory pricing controls and dependence on imported raw materials, which expose manufacturers to currency fluctuations and supply chain

constraints. The Company continued to manage these challenges through prudent operational planning and engagement with relevant regulatory authorities.

FINANCIAL HIGHLIGHTS

During the three-month period ended September 30, 2025, the Company recorded revenue of Rs. 8.821 million. Gross profit for the period amounted to Rs. 3.931 million.

Administrative, selling, and other operating expenses remained elevated during the period, resulting in an operating loss of Rs. 31.746 million. After accounting for finance costs and taxation, the loss after tax for the period stood at Rs. 30.157 million.

The Board remains focused on maintaining operational discipline and managing costs while navigating prevailing market conditions.

RELATED PARTY TRANSACTIONS

The Company ensures compliance with Code of Corporate Governance for all the related party transactions. The details of these transactions are provided in note no. 17 of the annexed financial statements.

EARNING PER SHARE

The loss per share (basic and diluted) for the three-month period ended September 30, 2025 was Rs. 0.32, as compared to earnings per share of Rs. 12.17 (basic) and Rs. 1.59 (diluted) in the corresponding period last year.

COMMITTEES OF THE BOARD

Audit committee

Audit committee comprises of three members from the Board. The chairman of the Board is an independent director as required in the CCG Regulations 2019 while the remaining two are non-executive directors. The Board of Directors has set out terms of reference for the audit committee. The audit committee reviews the annual and quarterly financial statements and holds its meeting prior to the Board meetings. The following are the members of the audit committee.

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Mr. Usman Mujib Shami	Member (Non-Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

Meeting And Attendance

Board Audit Committee: One (1) meeting has been convened during the three-month period ended September 30, 2025

Human Resource & Remuneration Committee

The committee consists of three members from the Board; one is independent director, one is non-executive director and the one is executive director. The Chairman of the committee is the

independent non-executive director. The committee reviews and formulates the HR & management policies of the company. The Committee is also responsible for the remuneration of employees and ensures that it is aligned with the Company's business strategy and long-term interests. The following are the members of the Human Resource committee.

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Ms. Firdous Shakir	Member (Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

Auditors

The external auditors of the Company, Reanda Haroon Zakaria Aamir Salman Rizwan & Co., Chartered Accountants, were re-appointed at the Annual General Meeting held on November 26, 2025, to hold office until the conclusion of the next Annual General Meeting, at a remuneration fixed by the Board of Directors.

DIVERSITY, EQUITY AND INCLUSION

The Company remains committed to promoting Diversity, Equity and Inclusion (DE&I) across its operations. Policies and practices aimed at fostering an inclusive and respectful workplace continue to be implemented, ensuring equal opportunity and a supportive environment for all employees. These initiatives are reviewed periodically to remain aligned with the Company's values and operational objectives.

ENVIRONMENT, HEALTH AND SAFETY

The Company continues to place strong emphasis on maintaining a safe and healthy working environment. Appropriate measures are in place to identify, assess, and mitigate occupational health and safety risks. Management remains committed to ensuring compliance with applicable safety standards and promoting a culture of safe working practices across all operations.

CORPORATE SOCIAL RESPONSIBILITY

During the period under review, the Company continued its commitment towards corporate social responsibility initiatives. These efforts primarily focus on community welfare, healthcare awareness, and support initiatives in areas surrounding the Company's operational facilities, in line with its CSR objectives.

ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Company has an adequate system of internal financial controls designed to ensure reliability of financial reporting, safeguarding of assets, and compliance with applicable laws and regulations. The effectiveness of these controls is reviewed periodically by management and overseen by the Audit Committee, with a view to continuous improvement.

STATE OF COMPANY'S AFFARIRS AND CORPORATE AND FINANCIAL REPORTING FRAMEWORK

The condensed interim financial statements have been prepared by the management and present fairly the state of the Company's affairs, results of operations, cash flows, and changes in equity for the period under review.

Appropriate accounting policies have been consistently applied, and accounting estimates are based on reasonable and prudent judgment. Proper books of account have been maintained, and the financial reporting framework is based on applicable International Accounting Standards as adopted in Pakistan.

There is no significant doubt regarding the Company's ability to continue as a going concern.

MATERIAL CHANGES

During the period under review, the Company undertook the following material corporate actions:

The Board of Directors, in its meeting held on July 22, 2025, recommended an increase in the authorized share capital of the Company from Rs. 1,000,000,000 (100,000,000 ordinary shares of Rs. 10/- each) to Rs. 1,200,000,000 (120,000,000 ordinary shares of Rs. 10/- each). The said increase, along with the consequential amendments to Clause V of the Memorandum of Association and Article 5 of the Articles of Association, was approved by the shareholders at the Extraordinary General Meeting held on August 18, 2025. The newly created shares rank pari passu with the existing ordinary shares.

Further, the Board of Directors, through a resolution dated September 12, 2025, approved the issuance of 20,000,000 ordinary shares of Rs. 10/- each as Right Shares at par, to be offered to the shareholders in the proportion of approximately 21.496 right shares for every 100 ordinary shares held, resulting in an increase in the paid-up share capital of the Company.

SUBSEQUENT EVENTS

There were no material events subsequent to the period end that require disclosure or adjustment in these condensed interim financial statements.

DIVIDENDS

No dividend has been declared during the period under review.

RISK OF MANAGEMENT AND RISK ASSESSMENT

The Board of Directors continues to oversee the Company's risk management framework. Key risks relating to operational, financial, regulatory, and market conditions are regularly identified and assessed. Appropriate controls and mitigation measures are in place to manage these risks, and the Audit Committee plays an active role in monitoring their effectiveness.

FUTURE CHALLENGES & PROSPECTS

The Board remains cautiously optimistic about the Company's prospects. Management continues to focus on operational efficiency, cost management, and sustainable growth while navigating prevailing market conditions. The Company is well-positioned to respond to challenges and pursue opportunities as they arise.

ACKNOWLEDGMENT

The Directors wish to express their appreciation to the Company's shareholders, employees, customers, vendors, and other stakeholders for their continued trust and support.

For and on behalf of the Board

Kaashif Hussain Siddique

Chief Executive Officer

Atif Hussain Siddique

Director

Dated: 02-January-2026

ڈائریکٹرز کی رپورٹ

ہم خوشی کے ساتھ 30 ستمبر 2025 کو ختم ہونے والی مدت کے لیے کمپنی کے مختصر عبوری مالی بیانات پیش کر رہے ہیں۔

بورڈ آف ڈائریکٹرز کی تشکیل

جنس کے اعتبار سے تقسیم

خواتین	مرد
1	6

ڈائریکٹرز کی تفصیل

نام	زمرہ
1.جناب احمد شعیب ہاشمی	آزاد ڈائریکٹر
2.جناب سید رضا عباس	آزاد ڈائریکٹر
1.جناب عاطف حسین	نان ایگزیکٹو ڈائریکٹر
2.جناب عمر مجیب شامی	نان ایگزیکٹو ڈائریکٹر
3.جناب عثمان مجیب شامی	نان ایگزیکٹو ڈائریکٹر
1.جناب کاشف حسین	ایگزیکٹو ڈائریکٹر
2.محترمہ فردوس شاکر (خاتون ڈائریکٹر)	ایگزیکٹو ڈائریکٹر

بنیادی سرگرمیاں

کمپنی کی بنیادی سرگرمی دواسازی مصنوعات کی تیاری اور فروخت ہے۔

معیشت اور کاروبار کا جائزہ

مجموعی معاشی جائزہ

30ستمبر 2025 کو ختم ہونے والی سہ ماہی کے دوران پاکستان کی مجموعی معاشی صورتحال مجموعی طور پر مستحکم رہی۔ اگرچہ مہنگائی اور لاگت سے متعلق دباؤ کاروباری سرگرمیوں کو متاثر کرتا رہا، تاہم اس عرصے میں کوئی ایسی نمایاں معاشی پیش رفت نہیں ہوئی جس نے کمپنی کی کارکردگی کو نمایاں طور پر متاثر کیا ہو۔

شعبے کی کارکردگی

دواسازی کا شعبہ اپنی لچک کا مظاہرہ کرتا رہا، جس کی بنیادی وجہ صحت سے متعلق ضروری مصنوعات کی مسلسل طلب رہی۔ صحت کی دیکھ بھال کی مستقل ضروریات اور ریگولیٹری اداروں کے ساتھ رابطہ اس شعبے کے استحکام میں معاون رہے۔

صنعتی چیلنجز

یہ شعبہ ریگولیٹری قیمتوں کے کنٹرول اور درآمد شدہ خام مال پر انحصار جیسے چیلنجز کا سامنا کرتا رہا، جس کے باعث زرِ مبادلہ میں اتار چڑھاؤ اور سپلائی چین کے مسائل پیدا ہوتے ہیں۔ کمپنی نے محتاط عملی منصوبہ بندی اور متعلقہ ریگولیٹری اداروں کے ساتھ رابطے کے ذریعے ان چیلنجز کو مؤثر انداز میں سنبھالا۔

مالی جھلکیاں

30ستمبر 2025 کو ختم ہونے والی تین ماہ کی مدت کے دوران کمپنی کی آمدن 8.821 ملین روپے رہی۔ اس عرصے کے دوران مجموعی منافع 3.931 ملین روپے رہا۔

انتظامی، فروخت اور دیگر آپریٹنگ اخراجات بلند سطح پر رہے، جس کے نتیجے میں آپریٹنگ نقصان 31.746 ملین روپے ہوا۔ مالی اخراجات اور ٹیکس کے بعد اس مدت کے لیے بعد از ٹیکس نقصان 30.157 ملین روپے رہا۔

بورڈ موجودہ مارکیٹ حالات میں لاگت کے مؤثر انتظام اور آپریشنل نظم و ضبط کو برقرار رکھنے پر توجہ مرکوز رکھے ہوئے ہے۔

متعلقہ فریقین کے ساتھ لین دین

کمپنی تمام متعلقہ فریقین کے ساتھ لین دین میں ضابطۂ کارپوریٹ گورننس کی مکمل پابندی کو یقینی بناتی ہے۔ ان لین دین کی تفصیلات منسلک مالی بیانات کے نوٹ نمبر 17 میں فراہم کی گئی ہیں۔

فی حصص آمدن

30ستمبر 2025 کو ختم ہونے والی تین ماہ کی مدت کے لیے فی حصص نقصان (بنیادی اور کم شدہ) 0.32 روپے رہا، جبکہ گزشتہ سال کی اسی مدت میں فی حصص آمدن 12.17 روپے (بنیادی) اور 1.59 روپے (کم شدہ) تھی۔

بورڈ کی کمیٹیاں

آڈٹ کمیٹی

آڈٹ کمیٹی بورڈ کے تین اراکین پر مشتمل ہے۔ ضابطۂ کارپوریٹ گورننس ریگولیشنز 2019 کے مطابق کمیٹی کے چیئرمین ایک آزاد ڈائریکٹر ہیں جبکہ باقی دو نان ایگزیکٹو ڈائریکٹرز ہیں۔ بورڈ آف ڈائریکٹرز نے آڈٹ کمیٹی کے لیے قواعد و ضوابط (TORs) مقرر کر رکھے ہیں۔ آڈٹ کمیٹی سالانہ اور سہ ماہی مالی بیانات کا جائزہ لیتی ہے اور بورڈ اجلاس سے قبل اپنے اجلاس منعقد کرتی ہے۔

آڈٹ کمیٹی کے اراکین

شمار	نام	عہدہ
i	جناب احمد شعیب ہاشمی	چیئرمین (آزاد ڈائریکٹر)
ii	جناب عاطف حسین صدیقی	رکن (نان ایگزیکٹو ڈائریکٹر)
iii	جناب عثمان مجیب شامی	رکن (نان ایگزیکٹو ڈائریکٹر)
iv	جناب محمد سعید	سیکریٹری

اجلاس اور حاضری: بورڈ آڈٹ کمیٹی کا ایک (1) اجلاس 30 ستمبر 2025 کو ختم ہونے والی تین ماہ کی مدت کے دوران منعقد ہوا۔

ہیومن ریسورس اور ریمونریشن کمیٹی

یہ کمیٹی بورڈ کے تین اراکین پر مشتمل ہے، جن میں ایک آزاد ڈائریکٹر، ایک نان ایگزیکٹو ڈائریکٹر اور ایک ایگزیکٹو ڈائریکٹر شامل ہیں۔ کمیٹی کے چیئرمین آزاد نان ایگزیکٹو ڈائریکٹر ہیں۔ کمیٹی کمپنی کی انسانی وسائل اور انتظامی پالیسیوں کا جائزہ لیتی اور انہیں مرتب

کرتی ہے۔ یہ کمیٹی ملازمین کے معاوضے کی بھی نگرانی کرتی ہے تاکہ یہ کمپنی کی کاروباری حکمتِ عملی اور طویل مدتی مفادات سے ہم آہنگ ہو۔

ہیومن ریسورس کمیٹی کے اراکین

شمار	نام	عہدہ
i	جناب احمد شعیب ہاشمی	چیئرمین (آزاد ڈائریکٹر)
ii	جناب عاطف حسین صدیقی	رکن (نان ایگزیکٹو ڈائریکٹر)
iii	محترمہ فردوس شاکر	رکن (ایگزیکٹو ڈائریکٹر)
iv	جناب محمد سعید	سیکریٹری

آڈیٹرز

کمپنی کے بیرونی آڈیٹرز، رینڈا ہارون زکریا عامر سلمان رضوان اینڈ کمپنی، چارٹرڈ اکاؤنٹنٹس، کو 26 نومبر 2025 کو منعقدہ سالانہ جنرل میٹنگ میں دوبارہ مقرر کیا گیا، جو اگلی سالانہ جنرل میٹنگ کے اختتام تک اپنے فرائض انجام دیں گے، اور ان کا معاوضہ بورڈ آف ڈائریکٹرز نے مقرر کیا۔

تنوع، مساوات اور شمولیت

کمپنی تنوع، مساوات اور شمولیت (DE&I) کے فروغ کے لیے پُرعزم ہے۔ ایک جامع اور باعزت کام کے ماحول کے فروغ کے لیے پالیسیوں اور طریقۂ کار پر عمل درآمد جاری ہے، تاکہ تمام ملازمین کو مساوی مواقع اور معاون ماحول فراہم کیا جا سکے۔ ان اقدامات کا وقتاً فوقتاً جائزہ لیا جاتا ہے۔

ماحولیات، صحت اور حفاظت

کمپنی محفوظ اور صحت مند کام کے ماحول کے قیام کو اولین ترجیح دیتی ہے۔ پیشہ ورانہ صحت اور حفاظت کے خطرات کی نشاندہی، جائزہ اور ان کے تدارک کے لیے مناسب اقدامات کیے گئے ہیں۔ انتظامیہ متعلقہ حفاظتی معیارات کی پابندی اور محفوظ کام کے طریقوں کے فروغ کے لیے پُرعزم ہے۔

کارپوریٹ سماجی ذمہ داری

زیرِ جائزہ مدت کے دوران کمپنی نے اپنی کارپوریٹ سماجی ذمہ داری کی سرگرمیوں کو جاری رکھا۔ یہ اقدامات بالخصوص کمیونٹی فلاح، صحت سے متعلق آگاہی اور کمپنی کی آپریشنل سہولیات کے اطراف کے علاقوں میں معاون سرگرمیوں پر مرکوز رہے۔

اندرونی مالی کنٹرولز کی کفایت

کمپنی کے پاس اندرونی مالی کنٹرولز کا مناسب نظام موجود ہے جو مالی رپورٹنگ کی درستگی، اثاثوں کے تحفظ اور قابلِ اطلاق قوانین و ضوابط کی تعمیل کو یقینی بناتا ہے۔ ان کنٹرولز کی مؤثریت کا باقاعدگی سے جائزہ لیا جاتا ہے اور آڈٹ کمیٹی اس کی نگرانی کرتی ہے۔

کمپنی کے امور اور کارپوریٹ و مالی رپورٹنگ کا فریم ورک

مختصر عبوری مالی بیانات انتظامیہ نے تیار کیے ہیں جو زیر جائزہ مدت کے دوران کمپنی کے امور، مالی نتائج، نقد بہاؤ اور ایکویٹی میں تبدیلیوں کی درست عکاسی کرتے ہیں۔

مناسب اکاؤنٹنگ پالیسیوں کا مستقل اطلاق کیا گیا ہے اور اکاؤنٹنگ تخمینے معقول اور محتاط بنیادوں پر تیار کیے گئے ہیں۔ حسابات کی مناسب کتابیں برقرار رکھی گئی ہیں اور مالی رپورٹنگ کا فریم ورک پاکستان میں نافذ بین الاقوامی اکاؤنٹنگ معیارات پر مبنی ہے۔کمپنی کی بطور جاری کاروبار صلاحیت کے حوالے سے کوئی نمایاں شبہ موجود نہیں ہے۔

اہم تبدیلیاں

زیر جائزہ مدت کے دوران کمپنی نے درج ذیل اہم کارپوریٹ اقدامات کیے:

بورڈ آف ڈائریکٹرز نے 22 جولائی 2025 کو منعقدہ اپنے اجلاس میں کمپنی کے مجاز شیئر کیپیٹل کو 1,000,000,000 روپے (100,000,000 عام حصص، ہر ایک کی مالیت 10 روپے) سے بڑھا کر 1,200,000,000 روپے (120,000,000 عام حصص، ہر ایک کی مالیت 10 روپے) کرنے کی سفارش کی۔ اس اضافے اور میمورنڈم آف ایسوسی ایشن کی شق V اور آرٹیکلز آف ایسوسی ایشن کے آرٹیکل 5 میں متعلقہ ترامیم کو 18 اگست 2025 کو منعقدہ غیر معمولی جنرل میٹنگ میں شیئر ہولڈرز نے منظور کیا۔ نئے جاری کردہ حصص موجودہ عام حصص کے برابر (pari passu) ہوں گے۔

مزید برآں، بورڈ آف ڈائریکٹرز نے 12 ستمبر 2025 کی قرارداد کے ذریعے 20,000,000 عام حصص، ہر ایک کی مالیت 10 روپے، کو رائٹ شیئرز کے طور پر جاری کرنے کی منظوری دی، جو موجودہ شیئر ہولڈرز کو تقریباً ہر 100 عام حصص پر 21.496 رائٹ شیئرز کے تناسب سے پیش کیے جائیں گے، جس کے نتیجے میں کمپنی کے ادا شدہ سرمایہ میں اضافہ ہوا۔

بعد از مدت واقعات

مدت کے اختتام کے بعد کوئی ایسا اہم واقعہ پیش نہیں آیا جس کے ان مختصر عبوری مالی بیانات میں انکشاف یا ایڈجسٹمنٹ کی ضرورت ہو۔

منافع

زیر جائزہ مدت کے دوران کوئی منافع (Dividend) اعلان نہیں کیا گیا۔

رسک مینجمنٹ اور رسک اسیسمنٹ

بورڈ آف ڈائریکٹرز کمپنی کے رسک مینجمنٹ فریم ورک کی نگرانی جاری رکھے ہوئے ہے۔ آپریشنل، مالی، ریگولیٹری اور مارکیٹ سے متعلق اہم خطرات کی باقاعدگی سے نشاندہی اور جانچ کی جاتی ہے۔ ان خطرات کے تدارک کے لیے مناسب کنٹرولز اور اقدامات موجود ہیں، اور آڈٹ کمیٹی ان کی مؤثریت کی نگرانی میں فعال کردار ادا کرتی ہے۔

مستقبل کے چیلنجز اور امکانات

بورڈ کمپنی کے مستقبل کے بارے میں محتاط طور پر پُرامید ہے۔ انتظامیہ آپریشنل کارکردگی، لاگت کے مؤثر انتظام اور پائیدار ترقی پر توجہ مرکوز رکھے ہوئے ہے، اور کمپنی درپیش چیلنجز کا مقابلہ کرنے اور نئے مواقع سے فائدہ اٹھانے کے لیے تیار ہے۔

شکریہ

ڈائریکٹرز کمپنی کے شیئر ہولڈرز، ملازمین، صارفین، سپلائرز اور دیگر تمام اسٹیک ہولڈرز کے اعتماد اور مسلسل تعاون پر دلی شکریہ ادا کرتے ہیں۔

برائے و بذریعہ بورڈ

کاشف یٰسین صدیقی
چیف ایگزیکٹو آفیسر

عاطف حسین صدیقی
ڈائریکٹر

بتاریخ: 02 جنوری، 2026

Liven Pharma Limited

CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT SEPTEMBER 30, 2025

	Note	UN-AUDITED September 30, 2025 (Rupees)	AUDITED June 30, 2025 (Rupees)
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	4	**660,510,062**	666,512,380
Intangible assets	5	**7,529,740**	8,440,679
Total non-current assets		**668,039,802**	674,953,059
CURRENT ASSETS			
Trade debts		**10,348,990**	9,402,578
Stock in trade		**109,884,091**	123,324,881
Tax refund due from government		**-**	-
Prepayments, deposits and advances		**11,236,864**	7,339,727
Cash and bank balances		**5,065,233**	7,884,396
Total current assets		**136,535,178**	147,951,582
TOTAL ASSETS		**804,574,980**	822,904,641
EQUITY AND LIABILITIES			
Share capital and reserves			
Share capital			
Authorized share capital		**1,200,000,000**	1,000,000,000
Issued, subscribed and paid-up share capital			
Issued, subscribed and paid-up share capital		**930,403,670**	930,403,667
Capital reserve			
Surplus on revaluation on property, plant and equipment		**-**	-
Revenue reserve			
Accumulated (loss)		**(326,700,748)**	(296,543,276)
Total equity		**603,702,922**	633,860,391
LIABILITIES			
NON-CURRENT LIABILITIES			
Lease liabilities	6	**1,084,277**	1,247,868
Long term financing	7	**4,208,602**	5,098,065
Deferred taxation		**90,501,377**	92,272,765
Total non-current liabilities		**95,794,256**	98,618,698
CURRENT LIABILITIES			
Trade and other payables		**72,069,262**	61,720,124
Loan from related parties	8	**18,047,263**	14,047,263
Running finance	9	**11,353,852**	11,185,166
Mark up accrued	10	**366,753**	386,020
Current portion of long term liabilities	11	**3,240,672**	3,086,979
Provision for taxation		**-**	-
Total current liabilities		**105,077,802**	90,425,552
Total liabilities		**200,872,058**	189,044,250
TOTAL EQUITY AND LIABILITIES		**804,574,980**	822,904,641
CONTINGENCIES AND COMMITMENTS	12		

The annexed notes form an integral part of these condensed interim financial statements.

Chief Executive	Director	Chief Financial Officer

Liven Pharma Limited

CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED) FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	Note	September 30, 2025 (Rupees)	September 30, 2024 (Rupees)
Revenue		**8,820,810**	88,909,727
Cost of sales		**(4,889,428)**	(64,098,804)
Gross profit		**3,931,382**	24,810,923
Administrative and general expenses		**(9,555,737)**	(4,680,003)
Selling and distribution expenses		**(4,765,879)**	-
Other expenses		**(20,720,838)**	-
Finance cost		**(634,636)**	-
Operating (loss) / profit		**(31,745,709)**	20,130,920
Other income	**13**	**4,032**	114,347,987
(Loss) / profit before levies and taxation		**(31,741,677)**	134,478,907
Levies	**14**	**(187,184)**	-
(Loss) / profit before taxation		**(31,928,861)**	134,478,907
Taxation	**15**	**1,771,388**	13,109,312
(Loss) / profit after taxation		**(30,157,472)**	147,588,219
(Loss) / profit per share			
-Basic	**16**	(0.32)	12.17
-Diluted		(0.32)	1.59

The annexed notes form an integral part of these condensed interim financial statements.

Chief Executive | **Director** | **Chief Financial Officer**

Liven Pharma Limited CEO

Liven Pharma Limited Director

Liven Pharma Limited

CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	Note	September 30, 2025 (Rupees)	September 30, 2024 (Rupees)
(Loss) / profit after taxation		**(30,157,472)**	147,588,219
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss		-	-
Items that will not be reclassified to profit or loss		-	-
Total other comprehensive income for the period		-	-
Total comprehensive (loss) / income for the period		**(30,157,472)**	147,588,219

The annexed notes form an integral part of these condensed interim financial statements.

Chief Executive	Director	Chief Financial Officer

Liven Pharma Limited

CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

Particulars	Share capital	Capital reserve	Revenue reserve	Total equity
	Issued, subscribed and paid-up share capital	Surplus on revaluation of property, plant and equipment	Accumulated (loss)/profit	
	....Rupees....			
Balance as at June 30, 2024 (Audited)	121,237,000	38,056,582	(293,089,484)	(133,795,902)
Transfer of retained earnings		(38,056,582)	38,056,582	-
Transaction with owners:				
Issued against loan to director	142,500,000	-	-	142,500,000
Issued as a result of merger arrangement	666,666,670	-	-	666,666,670
	809,166,670	-	-	809,166,670
Impact of merger arrangement	-	-	99,680,239	99,680,239
Profit for the three month period	-	-	147,588,219	147,588,219
Other comprehensive income for the three month period	-	-	-	-
Total comprehensive income for the period	-	-	147,588,219	147,588,219
Balance as at September 30, 2024 (Un-audited)	930,403,670	-	(7,764,444)	922,639,226
Balance as at June 30, 2025 (Audited)	930,403,670	-	(296,543,276)	633,860,394
Comprehensive income for the period:				
Loss for the three month period	-	-	(30,157,472)	(30,157,472)
Other comprehensive income for the three month period	-	-	-	-
Total comprehensive loss for the three month period	-	-	(30,157,472)	(30,157,472)
Balance as at September 30, 2025- (Un-audited)	930,403,670	-	(326,700,748)	603,702,922

The annexed notes form an integral part of these condensed interim financial statements.

Chief Executive | **Director** | **Chief Financial Officer**

Liven Pharma Limited CEO

Liven Pharma Limited Director

Liven Pharma Limited

CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	Note	September 30, 2025 (Rupees)	September 30, 2024 (Rupees)
CASH FLOWS FROM OPERATING ACTIVITIES			
(Loss) / profit before taxation		**(31,928,861)**	114,062,987
Adjustments for non cash and other items:			
Depreciation on property, plant and equipment		**5,838,459**	-
Depreciation on right of use assets		**383,858**	-
Amortization on intangible assets		**910,939**	-
Gain on sale of fixed assets		-	(85,424,621)
Liability written off		-	(28,923,366)
Allowance for expected credit loss		**677,398**	-
Finance cost		**634,636**	-
Operating (loss) / profit before working capital changes		**(23,483,570)**	(285,000)
Working capital changes			
Decrease / (increase) in current assets:			
Stock in trade		**13,440,786**	-
Trade debts		**(1,623,810)**	-
Prepayments, deposits and advances		**(3,897,137)**	-
(Decrease) / increase in current liabilities:			
Trade and other payables		**10,349,138**	-
Decrease in accured liabilities		-	(164,548)
Cash (used in) operations	**A**	**(5,214,593)**	(449,548)
Finance cost paid		**(588,825)**	-
Taxes paid		-	-
Net cash (used in) operating activities		**(5,803,418)**	(449,548)
CASH FLOWS FROM INVESTING ACTIVITIES			
Adjustment of loan against disposal of fixed assets		-	205,080,348
Net cashflows from merger		-	4,340,679
Payments for acqusisition of property, plant and equipment		**(220,000)**	-
Net cash used in / generated from investing activities	**B**	**(220,000)**	209,421,027
CASH FLOWS FROM FINANCING ACTIVITIES			
Adjustment of loan against the disposal of fixed assets			(204,636,018)
Payments against lease liabilities		**(203,846)**	
Receipt of loan from related party		**4,000,000**	-
Proceeds from running finance		**22,305,353**	-
Repayments against running finance		**(22,136,664)**	-
Repayments against long term finance		**(760,588)**	
Net cash generated from / (used in) financing activities	**C**	**3,204,255**	(204,636,018)
Net (decrease)/increase in cash and cash equivalents	**A+B+C**	**(2,819,163)**	4,335,461
Opening cashflows of amalgamated entity		-	24,955,329
Cash and cash equivalents at the beginning of the period		**7,884,396**	38,000
Cash and cash equivalents at the end of the period		**5,065,233**	29,328,790

The annexed notes form an integral part of these condensed interim financial statements.

Chief Executive | Director | Chief Financial Officer

Liven Pharma Limited CEO

Liven Pharma Limited Director

Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

1 STATUS AND NATURE OF BUSINESS

1.1 Liven Pharma Limited (Formerly: Landmark Spinning Industries Limited) (the Company) was registered on October 21, 1991 under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017) as a private limited Company in Pakistan and subsequently converted into public limited Company as on April 30, 1992. The shares of the Company are quoted on Pakistan Stock Exchange Limited (PSX). The principal activity of the Company was trading, manufacturing, and selling of yarn. The Company changed its principle line of business under the scheme of arrangement sanctioned by the Honorable High Court of Sindh, Karachi and the principal line of business has been changed from "Textile Spinning" to "Pharmaceuticals."

The Company changed its registered office under the arrangement sanctioned by the Honorable High Court of Sindh, Karachi from Sindh to Punjab.

The registered office and manufacturing facility of the Company is located at 49-KM, Multan Road, Phool Nagar District Kasur.

1.2 During this previous year, the Scheme of Arrangement dated April 25, 2022, for the amalgamation of the entire business and operations of Liven Pharmaceuticals (Private) Limited ("LPL") into the Company was sanctioned by the Honorable High Court of Sindh, Pakistan, on September 2, 2024. As a result of the Court's approval, all assets, rights, liabilities, and obligations of LPL have been amalgamated, transferred, and vested into the Company. This includes adjustments for the factory land, building, plant, and machinery located at Winder Industrial Estate, Sector C, District Lasbella, Baluchistan, which have been settled against the loan from related parties associated with the Company's current sponsors in accordance with the Scheme of Arrangement.

Owing to the implementation of Scheme of Arrangement sanctioned by the Honorable High Court of Sindh, Karachi :

- the name of the Company changed from "Landmark Spinning Industries Limited" to "Liven Pharma Limited."
- the principal line of business of the Company changed from "textile spinning" to "pharmaceuticals."
- the registered office of the Company changed from "Sindh" to "Punjab."
- Authorized share capital of the Company increased to Rs. 1 billion.

1.3 During the period under review, the Company undertook the following material corporate actions:

The Board of Directors, in its meeting held on July 22, 2025, recommended an increase in the authorized share capital of the Company from Rs. 1,000,000,000 (100,000,000 ordinary shares of Rs. 10/- each) to Rs. 1,200,000,000 (120,000,000 ordinary shares of Rs. 10/- each). The said increase, along with the consequential amendments to Clause V of the Memorandum of Association and Article 5 of the Articles of Association, was approved by the shareholders at the Extraordinary General Meeting held on August 18, 2025. The newly created shares rank pari passu with the existing ordinary shares.

Further, the Board of Directors, through a resolution dated September 12, 2025, approved the issuance of 20,000,000 ordinary shares of Rs. 10/- each as Right Shares at par, to be offered to the shareholders in the proportion of approximately 21.496 right shares for every 100 ordinary shares held, resulting in an increase in the paid-up share capital of the Company.

Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

2 BASIS OF PREPARATION

2.1 Basis of measurement

The Company is considered a going concern entity and these financial statements have been prepared on going concern basis.

2.2 Statement of compliance

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, "Interim Financial Reporting", issued by the International Accounting Standard Board (IASB) as notified under the Companies Act 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with requirements of IAS 34, provisions of and directives issued under the Companies Act, 2017 have been followed.

2.3 Basis of measurement

These condensed interim financial statements have been prepared under the historical cost convention using accrual basis of accounting, except for certain items as disclosed in the relevant accounting policies below.

3 MATERIAL ACCOUNTING POLICY INFORMATION

3.1 The material accounting policy information and methods of computations adopted for the preparation of these condensed interim financial statements are the same as applied in the preparation of the preceding annual audited published financial statements of the Company for the year ended 30 June 2025.

3.2 The preparation of these condensed interim financial statements in conformity with the approved accounting standards requires the use of certain critical accounting estimates. It also requires the management to exercise its judgment in the process of applying the Company's accounting policies. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

During preparation of these condensed interim financial statements, the significant judgments made by the management in applying the Company's accounting policies and the key sources of estimation and uncertainty were the same as those that applied in the preceding annual audited published financial statements of the Company for the year ended 30 June 2025.

Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

4 PROPERTY, PLANT AND EQUIPMENT

UN-AUDITED								
Description	COST			Rate %	DEPRECIATION			WDV
	As on July 01, 2025	Additions	As on September 30, 2025		As on July 01, 2025	Charge for the year	As on September 30, 2025	As on September 30, 2025
	Rupees				Rupees			
Owned assets								
Freehold land	105,750,000	-	105,750,000		-	-	-	105,750,000
Buildings on freehold land	247,954,713	-	247,954,713	5%	49,745,045	2,477,621	52,222,666	195,732,047
Plant and machinery	400,628,718	-	400,628,718	3%	64,122,058	2,523,800	66,645,858	333,982,860
Labortory equipment	13,264,026	-	13,264,026	20%	9,303,410	198,031	9,501,440	3,762,586
Office equipment	542,044	-	542,044	20%	182,003	18,002	200,005	342,039
Generators	1,360,500	-	1,360,500	20%	909,119	22,569	931,688	428,812
Furniture and fixture	6,778,413	-	6,778,413	10%	3,158,760	90,491	3,249,251	3,529,162
Computer and accessories	911,103	220,000	1,131,103	30%	767,705	16,255	783,960	347,143
Motor vehicles	11,010,653	-	11,010,653	20%	1,176,853	491,690	1,668,543	9,342,110
Total owned asset	**788,200,170**	**220,000**	**788,420,170**		**129,364,953**	**5,838,459**	**135,203,411**	**653,216,759**
Leased assets								
Motor vehicles	15,741,332	-	15,741,332	20%	8,064,170	383,858	8,448,028	7,293,304
Total leased assets	**15,741,332**	**-**	**15,741,332**		**8,064,170**	**383,858**	**8,448,028**	**7,293,304**
Total September 30, 2025	**803,941,502**	**220,000**	**804,161,502**		**137,429,123**	**6,222,317**	**143,651,440**	**660,510,062**

AUDITED								
Description	COST			Rate %	DEPRECIATION			WDV
	As on July 01, 2024	Additions	As on June 30, 2025		As on July 01, 2024	Charge for the year	As on June 30, 2025	As on June 30, 2025
	Rupees				Rupees			
Owned assets								
Freehold land	105,750,000	-	105,750,000		-	-	-	105,750,000
Buildings on freehold land	247,954,713	-	247,954,713	5%	39,312,957	10,432,088	49,745,045	198,209,668
Plant and machinery	388,931,474	11,697,244	400,628,718	3%	53,991,259	10,130,800	64,122,058	336,506,660
Labortory equipment	13,264,026	-	13,264,026	20%	8,313,256	990,154	9,303,410	3,960,616
Office equipment	273,344	268,700	542,044	20%	135,151	46,852	182,003	360,041
Generators	1,360,500		1,360,500	20%	796,274	112,845	909,119	451,381
Furniture and fixture	6,778,413	-	6,778,413	10%	2,756,576	402,184	3,158,760	3,619,653
Computer and accessories	911,103	-	911,103	30%	706,249	61,456	767,705	143,398
Motor vehicles	140,528	10,870,125	11,010,653	20%	77,168	1,099,685	1,176,853	9,833,801
Total owned asset	**765,364,101**	**22,836,069**	**788,200,170**		**106,088,889**	**23,276,063**	**129,364,953**	**658,835,218**
Leased assets								
Motor vehicles	12,942,332	2,799,000	15,741,332	20%	6,669,692	1,394,478	8,064,170	7,677,162
Total leased assets	**12,942,332**	**2,799,000**	**15,741,332**		**6,669,692**	**1,394,478**	**8,064,170**	**7,677,162**
Total June 30, 2025	**778,306,433**	**25,635,069**	**803,941,502**		**112,758,581**	**24,670,541**	**137,429,123**	**666,512,380**

Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	Note	(UN-AUDITED) September 30, 2025 (Rupees)	(AUDITED) June 30, 2025 (Rupees)
5 INTANGIBLE ASSETS			
Intangible assets - Definite useful life	5.1	7,529,740	8,440,679
		7,529,740	8,440,679

5.1 Intangible assets - Definite useful life

Reconciliation of the carrying amounts at the beginning and end of the year is as follows:

UN-AUDITED			
Particulars	**ERP system**	**Patents**	**Total**
	——— Rupees ———		
Cost	6,426,000	10,000,000	16,426,000
Accumulated amortization	(5,485,321)	(2,500,000)	(7,985,321)
Net book value - July 01, 2025	940,679	7,500,000	8,440,679
Opening net book value	940,679	7,500,000	8,440,679
Additions during the year	-	-	-
Amortization for the year	(77,606)	(833,333)	(910,939)
Net book value - September 30, 2025	863,073	6,666,667	7,529,740
Cost	6,426,000	10,000,000	16,426,000
Accumulated amortization	(5,562,927)	(3,333,333)	(8,896,260)
Net book value - September 30, 2025	863,073	6,666,667	7,529,740
Rate of amortization	33%	33%	
Method of amortization	Diminishing balance method	Straight line basis	
Remaining useful life	-	2 years	

AUDITED			
Particulars	**ERP system**	**Patents**	**Total**
	——— Rupees ———		
Cost	6,426,000	-	6,426,000
Accumulated amortization	(5,022,002)	-	(5,022,002)
Net book value - July 01, 2024	1,403,998	-	1,403,998
Opening net book value	1,403,998	-	1,403,998
Additions during the year	-	10,000,000	10,000,000
Amortization for the year	(463,319)	(2,500,000)	(2,963,319)
Net book value - June 30, 2025	940,679	7,500,000	8,440,679
Cost	6,426,000	10,000,000	16,426,000
Accumulated amortization	(5,485,321)	(2,500,000)	(7,985,321)
Net book value - June 30, 2025	940,679	7,500,000	8,440,679
Rate of amortization	33%	33%	
Method of amortization	Diminishing balance method	Straight line basis	
Remaining useful life	-	2 years 3 months	

5.2 The amortization charge for the year has been allocated as follows:

	(UN-AUDITED) September 30, 2025 (Rupees)	(AUDITED) June 30, 2025 (Rupees)
Administrative expenses	77,606	463,319
Cost of revenue	833,333	2,500,000
	910,939	2,963,319

Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	Note	(UN-AUDITED) September 30, 2025 (Rupees)	(AUDITED) June 30, 2025 (Rupees)
6 LEASE LIABILITY			
Present value of minimum lease payments against right of use asset	6.1	**1,697,822**	1,836,591
Less: Current maturity		**(613,545)**	(588,723)
		1,084,277	1,247,868
6.1 Reconciliation:			
Opening balance		**1,836,591**	395,413
Additions		-	2,799,000
Interest expense charged during the period		**65,078**	109,403
Lease rental payments made during the period		**(203,847)**	(1,467,225)
		1,697,822	1,836,591
Current maturity presented under current liabilities		**(613,545)**	(588,723)
Present value of minimum lease payments		**1,084,277**	1,247,868

6.2 Maturity analysis of lease liabilities

- The future minimum lease payments to which the Company is committed under the agreement will be due as follows:

Minimum lease payments:		
Not later than 1 year	**813,296**	815,383
Later than 1 year but not later than 5 years	**1,209,042**	1,426,920
Later than 5 years	-	-
	2,022,338	2,242,303
Finance cost allocated to future periods	**(324,516)**	(405,712)
Present value of minimum lease payments	**1,697,822**	1,836,591

6.3 The Company had total cash outflows for leases during the period is Rs. 203,847/- (2025: Rs.1,467,225/-).

6.4 Interest expense amounting Rs. 65,078/- (2025: Rs. 109,403/-) is charged to statement of profit or loss.

6.5 These represent liabilites against right-of-use assets of the Company for lease contracts of motor vehicle. The rentals are payable on monthly basis over a tenor ranging from 3 to 5 periods. The cash outflows are discounted at lessee's incremental borrowing rate of 15.03% per annum (6 month KIBOR +3% risk spread at the date of inception of lease contracts). The Company has the option to transfer the ownership of the motor vehicle in its name upon completion of the lease term.

7 LONG TERM FINANCING			
From banking companies - secured			
Long term finances	7.1	**6,835,729**	7,596,321
Less: current portion shown under current liabilities		**(2,627,127)**	(2,498,256)
Non-current portion		**4,208,602**	5,098,065

7.1 The Company obtained long term finance facility of Rs 8.038 million from Bank AL-Habib Limited (the Bank) under Term Finance Facility. The mark-up payments under this facility are calculated on the basis of 6 months KIBOR plus 3% and is paid on monthly basis.

The loan was secured against:
1st hypo charge over current assets of the company for Rs 21.33M, registered with SECP.
TRM of Rs 500,000 and EM for Rs 100M over industrial property situated at hadbast mouza kamongal, 49 KM lahore multan road, adjacent nishat chunian mills / millat battery, tehsil pattoki district kasur vide khasra no 2405, 2401, 2400 measuring 21 kanal 03 marlas owned by Mr. Atif Siddique and Mr. Kashif Hussain Siddique (Directors of the Company) having market value of Rs. 102M and forced sale value of Rs 83M (Land market value of Rs 29M and forced sale value of Rs 24M) valuated by Harvester Services Private Ltd dated 22-06-2021. (building market value Rs 73M and forced sale value Rs 58M).
Personal guarantees of the directors of the Company.
Trust receipt.
30% Security Deposit for LF-I, LF-II and TF-III.
Vehicles registered in the name of Bank Al Habib Limited duly insured LF-I and II.
Specific charge over vehicles registered with SECP for Rs 3.183M for LF-I.
Specific charge over vehicles registered with SECP for Rs 3.633M for LF-II.
30% Down Payment.
Specific charge over Generator registered with SECP for Rs.600,000 for TF-II.
Specific charge over vehicle registered with SECP for Rs.1.940M for TF-III.

Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

20% cash margin or as per SBP directive whichever is higher.
Lien over shipping documents.
Accepted draft.
Truck receipt.

	Note	(UN-AUDITED) September 30, 2025 (Rupees)	(AUDITED) June 30, 2025 (Rupees)
8 LOAN FROM RELATED PARTIES			
Unsecured - considered good			
Loan from director		**18,047,263**	14,047,263
		18,047,263	14,047,263
8.1 Loan from directors			
Mr. Kashif Hussain Siddique		**18,047,263**	14,047,263
		18,047,263	14,047,263

8.1.1 During the period, un-secured interest free loan obtained, for meeting working capital requirements of the company, from Mr. Kashif Hussain Siddique, CEO of the Company, amounting Rs. 4,000,000/- which is payable on demand.

9 RUNNING FINANCE			
From banking companies - Secured			
Running finance		**11,353,852**	11,185,166
		11,353,852	11,185,166

9.1 This represents short term financing having sanctioned limit of Rs. 13 million obtained by the Company from Bank AL Habib Limited.

9.2 The facility is to be adjusted within 90 days from the operating cash flows of the company. This carries markup at the rate of matching tenure KIBOR + 3% per annum. This loan is secured against collaterals as mentioned in note 7.1.

10 MARK UP ACCRUED			
Markup accrued on running finance facility	**9**	**366,753**	325,745
Markup accrued on long term finance	**7**	-	60,275
		366,753	386,020
11 CURRENT PORTION OF LONG TERM LIABILITIES			
Current portion of lease liabilities	**6**	**613,545**	588,723
Current portion of long term financing	**7**	**2,627,127**	2,498,256
		3,240,672	3,086,979

12 CONTINGENCIES AND COMMITMENTS

12.1 Contingencies
- There are no contingencies of the Company as at the reporting date (June 30, 2025: Nil).

12.2 Commitments
- There are no commitments of the Company as at the reporting date except as disclosed in note 6.2. (June 30, 2025: same).

13 OTHER INCOME			
Profit on bank deposits		**4,032**	305,814
		4,032	305,814
14 LEVIES			
Minimum tax u/s 113	**14.1**	**110,260**	1,590,899
Adjustment for the prior period		**76,924**	-
		187,184	1,590,899

14.1 This represents portion of minimum tax under section 113 of Income Tax Ordinance (ITO, 2001), representing levy in terms of requirements of IFRIC 21/IAS 37.

Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	Note	(UN-AUDITED) September 30, 2025 (Rupees)	(AUDITED) June 30, 2025 (Rupees)
14.2 Reconciliation of current tax charge charged as per tax laws for the period, with current tax recognised in the profit and loss account, is as follows:			
Current tax liability for the period as per applicable tax laws		**110,260**	1,590,899
Portion of current tax liability as per tax laws, representing income tax under IAS 12		-	-
Portion of current tax computed as per tax laws, representing levy in terms of requirements of IFRIC 21/IAS 37		**(110,260)**	(1,590,899)
Difference		-	-

15 TAXATION

Current tax		
- Charge for the period	-	-
Deferred tax		
-Adjustment attributable to origination and reversal of temporary differences	**1,771,388**	92,272,765
	1,771,388	92,272,765

15.1 Reconciliation of tax expense and product of accounting profit multiplied by the applicable tax rate and numerical reconciliation between the average tax rate and the applicable tax rate is not provided due to the applicability of minimum turnover tax (2025: Same).

16 LOSS PER SHARE - BASIC AND DILUTED

Net (loss)/profit for the period attributable to ordinary shareholders (Rupees)	**(30,157,472)**	(584,459,523)
Weighted average number of ordinary shares outstanding during the period (Number)	**93,040,367**	69,790,275
(Loss)/ Earning per share (Rupees)	**(0.32)**	(8.37)

16.1 There is no difference between basic and diluted earnings/loss per share as the company has not issued any instruments carrying options which would have an impact on earnings per share when exercised.

17 TRANSACTIONS WITH RELATED PARTIES

The related parties comprise of associated companies/undertakings, directors of the Company and key management personnel. Details of transactions with related parties during the period other than those which have been disclosed elsewhere in these financial statements are stated below:

Name of related party	Nature of relationship	Transaction Details	Sep 30, 2025	June 30, 2025
Key Management Personnel:				
Mr. Kaashif Hussain Siddiquie	Chief Executive Officer & Shareholder : 43.48%	Expense incurred on behalf of company	-	14,047,263
		Shares issued against loan from director	-	71,250,000
		Working capital requirements	**4,000,000**	-
Mr. Atif Hussain Siddiquie	Director & Shareholder : 43.48%	Shares issued against loan from director	-	71,250,000

18 CORRESPONDING FIGURES

- In order to comply with the requirements of International Accounting Standard (IAS) 34 "Interim Financial Reporting", the condensed interim statement of financial position and the condensed interim statement of changes in equity have been compared with the balances of the annual audited financial statements of the preceding financial year, whereas the condensed interim statement of profit or loss, condensed interim statement of comprehensive income, and condensed interim statement of cash flows have been compared with the balances of the comparable period of the immediately preceding financial year.

19 AUTHORIZATION OF FINANCIAL STATEMENTS

19.1 These condensed interim financial statements for the period ended Septemeber 30, 2025 were approved by the Board of directors and authorized for issue on January 02, 2026.

20 GENERAL

- Figures have been rounded off to the nearest Pakistan Rupees (PKR), unless otherwise stated.

Chief Executive	Director	Chief Financial Officer

Liven Pharma Limited CEO

Liven Pharma Limited Director